Vaccari, Monica
Fourati, Slim http://orcid.org/0000-0001-6609-7587
Gordon, Shari N.
Brown, Dallas R.
Bissa, Massimilano
Schifanella, Luca
Silva de Castro, Isabela
Doster, Melvin N.
Galli, Veronica
Omsland, Maria
Fujikawa, Dai
Gorini, Giacomo
Liyanage, Namal P. M.
Trinh, Hung V.
McKinnon, Katherine M.
Foulds, Kathryn E.
Keele, Brandon F.
Roederer, Mario
Koup, Richard A.
Shen, Xiaoying
Tomaras, Georgia D.
Wong, Marcus P.
Munoz, Karissa J.
Gach, Johannes S.
Forthal, Donald N.
Montefiori, David C.
Venzon, David J.
Felber, Barbara K.
Rosati, Margherita
Pavlakis, George N.
Rao, Mangala
Sekaly, Rafick-Pierre
Franchini, Genoveffa
Article History
Received: 18 December 2017
Accepted: 7 March 2018
First Online: 21 May 2018
Competing interests
: The US Government in conjunction with Sanofi Pasteur holds Patent 5766598: A Recombinant Attenuated ALVAC Canarypox virus Expression Vectors Containing Heterologous DNA Segments Encoding Lentiviral Gene, inventors E. Paoletti, J. Tartaglia and W. I. Cox, issued 16 June 1998, for the ALVAC vaccine. The US Government also holds Patent 7094408: Improved Immunogenicity Using a Combination of DNA and Vaccinia Virus Vector Vaccines, inventors G. Franchini, Z. Hel and G. Pavlakis, issued 22 August 2006. This patent is for the combination DNA and ALVAC poxvirus vaccines.